TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03491111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training for EMT+IMT
Description: 2 times per day and 5 day per week, 6 weeks, training with breathing trainer.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Rehabilitation
Description: Regular Rehabilitation: 2-3 times a week, 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Rehabilitation
Description: Regular Rehabilitation: 2-3 times a week, 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Rehabilitation
Description: Regular Rehabilitation: 2-3 times a week, 6 weeks.
Study: NCT03481010

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PAO with hip arthroscopy
Description: Participants who are randomized to the Scope-PAO group will receive central compartment hip arthroscopy in addition to the PAO.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PAO without hip arthroscopy
Description: Participants who are randomized to the PAO-only group will receive a Bernese Periacetabular Osteotomy (PAO) for treatment of hip dysplasia.
Study: NCT03491111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training for EMT
Description: 5 sets, 5 repetition with one or two minute of rest between sets, twice per day, 5 days per week, training with breathing trainer.
Study: NCT03041896

Intervention type: DEVICE
Intervention: coflex® Interlaminar Technology
Description: Interlaminer Technology
Study: NCT04342455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: double-low scanning
Description: a CT angiography protocol with low radiation and contrast agent exposure
Study: NCT01380600

Intervention type: DRUG
Group type: OTHER
Intervention: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Description: Intravenous Dose Range: 1x10\^6 pfu/kg, 1x10\^7 pfu/kg, 3x10\^7 pfu/kg Up to 4 intravenous infusions administered over 60 minutes every 2 weeks.
Study: NCT04038138

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Validation of new COA for FSHD patients
Description: Monitoring of commonly used and news COA in patients with facioscapulohumeral muscular dystrophy
Study: NCT02393352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling Therapy
Description: The dry needling therapy will be applied on active trigger points in occipital muscle, splenius capitis, sternocleidomastoid muscle, scalene muscles, trapezius, supraspinatus, infraspinatus muscle, latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourm muscles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulation Therapy
Study: NCT04201184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Newly created cultural components, adapted Family Spirit lessons, adapted CETA modules
Description: Caregivers will receive 12 lessons, weekly, over a period of 12 weeks. Full curriculum contains: 4 lessons on cultural connection and traditions, 4 lessons on parenting adapted from Family Spirit intervention, and 4 lessons on stress and trauma adapted from CETA. modules
Study: NCT04201184

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active nutrition control
Description: The active control condition will receive nutrition information, weekly food boxes and recipes. Recipes will be developed based on seasonal foods and a shopping list for making future meals will be included.
Study: NCT03041896

Intervention type: DEVICE
Intervention: coflex® Interlaminar Technology
Description: Interlaminer Technology

Intervention type: DEVICE
Intervention: coflex® Interlaminar Technology
Description: Interlaminer Technology
Study: NCT02408263

Intervention type: PROCEDURE
Intervention: Total Hip Replacement (THR) and Total Knee Replacement (TKR)
Description: Total Hip Replacement is a surgical procedure where the cartilage and bone of the hip joint is replaced with artificial materials. Total Knee Replacement involves replacement of all three compartments of the knee the medial, the lateral and patellofemoral compartment.
Study: NCT03679871

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire validation
Description: Participants will fill in the questionnaire Spiritual Resources and Distressplus additional questionnaires required for validation purposes. Three weeks later, a sub-sample will fill in the questionnaire one more time for consistency testing (test-retest)
Study: NCT04327245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention ingest a 5000 mg of D-tagatose
Description: Woman with resistance insulin who ingest a 5000 mg of D-tagatose. D-tagatose is a sweetener of natural origin, low in calories (1.5 kcal / g) and with a sweetness power of 0.9.~About 20 to 25% of the ingested D-tagatose is absorbed and metabolized in the liver, the rest is fermented by the microbiota producing short chain fatty acids.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention ingest a 15,3 mg of stevia
Description: Woman with resistance insulin who ingest a 15,3 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet. Steviol glycosides are up to 300 times sweeter than sucrose, do not provide calories and can be used as a substitute for sucrose or as a non-nutritive sweetener alternative. Your allowable daily intake is 4 mg / kg / body weight (expressed as steviol)
Study: NCT00745004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Over-encapsulated 4mg ondansetron tablets. Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days. For 5 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule matching over-encapsulated experimental drug. 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days. For 5 weeks.
Study: NCT02651038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: Measurement of PK
Study: NCT03647098

Intervention type: DRUG
Intervention: Chemotherapy.
Description: pemetrexed, 500mg/m2, ivgtt every 21 day.

Intervention type: DRUG
Intervention: Chemotherapy.
Description: pemetrexed, 500mg/m2, ivgtt every 21 day.

Intervention type: DRUG
Intervention: Chemotherapy.
Description: pemetrexed, 500mg/m2, ivgtt every 21 day.

Intervention type: DRUG
Intervention: Chemotherapy.
Description: pemetrexed, 500mg/m2, ivgtt every 21 day.

Intervention type: DRUG
Intervention: Chemotherapy.
Description: pemetrexed, 500mg/m2, ivgtt every 21 day.
Study: NCT00222066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetal ovarian cyst aspiration
Description: Fetal ovarian cyst aspiration performed under ultrasound guidance and maternal local anesthesia
Study: NCT02950168

Intervention type: PROCEDURE
Intervention: Edoxaban
Description: Edoxaban according to Summary of Product Characteristic (SMPC)
Study: NCT00520273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cobas s 201 TaqScreen MPX Test
Description: Donors testing reactive for one or more of the viral markers will be advised to seek further advice/treatment from their physician.
Study: NCT02206230

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard radiation therapy
Study: NCT02023515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional brain training
Description: Stress management based program
Study: NCT04481217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-questionnaires battery
Description: * Childhood trauma questionnaire (Bernstein, Ahluvalia, Pogge, \& Handelsman, 1997; Bernstein et al., 2003)~* The Young schema questionnaire short form (SQ-SF ; Cottraux \& Black, 2006; Young, 1998).~* Dissociative experiences scale (Laroi et al., 2013).~* Launay-Slade hallucination scale (Bentall \& Slade, 1985; Launay \& Slade, 1981)~* Cardiff Anomalous Perceptions Scale (Bell et al., 2006)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Socio-demographic screening
Description: age; gender; education; highest diploma; job; marital status; living place
Study: NCT02023515

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral weight loss
Description: Standard behavioral weight loss
Study: NCT03773887

Intervention type: OTHER
Group type: OTHER
Intervention: collection of liver biopsies collection of blood samples
Description: blood and ascites samples; extraction of explants, hepatic resection parts; hepatic parenchyma on liver biopsies

Intervention type: OTHER
Group type: OTHER
Intervention: collection of liver biopsies collection of blood samples
Description: blood and ascites samples; extraction of explants, hepatic resection parts; hepatic parenchyma on liver biopsies

Intervention type: OTHER
Group type: OTHER
Intervention: collection of liver biopsies collection of blood samples
Description: blood and ascites samples; extraction of explants, hepatic resection parts; hepatic parenchyma on liver biopsies
Study: NCT00788892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Study: NCT03774277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Packed Promise for a Healthy Heart
Description: Voucher for fresh vegetables and fruits (referred to as a fresh check); Home delivered food boxes that contain Dietary Approaches to Stop Hypertension (DASH)-approved ingredients for preparing low-salt, and traditional healthy Chickasaw meals; Heart-healthy recipes (available at getfreshcooking.com) that are tailored to traditional Chickasaw diet and culture; Educational materials; Personalized invitation to attend local cooking demonstrations; Assistance to link the Fitbit and AYA app
Study: NCT02519127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycaemic load diet
Description: Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a low glycemic load diet for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Western diet
Description: Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a 'Western' diet for 6 weeks.
Study: NCT02445963

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shigella flexneri 2a InvaplexAR
Description: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shigella flexneri 2a InvaplexAR
Description: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shigella flexneri 2a InvaplexAR
Description: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shigella flexneri 2a InvaplexAR
Description: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.
Study: NCT03876626

Intervention type: OTHER
Group type: OTHER
Intervention: PositiveLinks RX Mobile App
Description: A mobile app designed with tools to facilitate patient self-monitoring, patient-provider communication, medication refills, and social support.

Intervention type: OTHER
Group type: OTHER
Intervention: PositiveLinks RX Portal
Description: An online portal that interacts with the mobile app to enable users to engage with participants though messaging and medication refill tracking.
Study: NCT00426101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10 mg/m2 daily wk 1-2 5 mg/m2 daily wk 3-4 2.5 mg/m2 daily wk 5-6 1.25 mg/m2 daily wk 7 Steroids tapered wk 8~If continuation:~Pulses every 2nd wk, 10 mg/m2 for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m2 iv twice/wk (wk 1-2) 150 mg/m2 iv once/wk (wk 3-8)~If continuation:~150 mg/m2 iv, every 2nd wk

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Description: WK 1-8:~- Aim at around 200 microgram/L (trough value). Start: 6 mg/kg daily (divided in 2 daily doses) wk 1, if kidney function is normal.~If continuation:~- Aim for around 200 microgram/L. Monitor GFR.
Study: NCT02209974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: Administration of inhaled corticosteroids (fluticasone, 0.5 mg) each 12 hours to 8 of the 16 COPD patients versus placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Study: NCT02643732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate (overencapsulated)
Description: 10mg (1 capsule) methylphenidate (standard release) twice daily, increased to 20mg (2 capsules) twice daily after 2 weeks. The drug can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
Study: NCT03872089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infrared Thermography
Description: Measurements of the temperature of the plantar arch by thermal imaging (Infrared Thermography)
Study: NCT02482103

Intervention type: PROCEDURE
Intervention: Renal denervation
Description: Catheter based renal nerve ablation
Study: NCT03098537

Intervention type: DRUG
Group type: OTHER
Intervention: enteral nutrition + proton pump inhibitor
Description: Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive enteral nutrition and proton pump inhibitor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: enteral nutrition only
Description: Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive only enteral nutrition.
Study: NCT00537381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 as intravenous infusion every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 as intravenous infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg orally twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 5 mg orally twice daily.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intetumumab
Description: Intetumumab 10 mg/kg as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
Study: NCT02643732

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Over-encapsulated tablet)
Description: Identical capsules (over-encapsulated placebo tablets), administered initially one capsule twice daily, increased to 2 capsules after 2 weeks. As with the methylphenidate arm, the dose can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
Study: NCT04325230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arterial Spin Labeling sequence
Description: ASL sequence added to the usual care brain MRI
Study: NCT03594812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45º. The application was in capacitive mode, with a 5 cm electrode, always in movement. The duration of the application was established in 20 minutes, maintaining the local temperature between 40ºC to 42 ºC at the epidermis.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Radiofrequency without power
Description: Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45ºC (Celsius degrees). The application was in capacitive mode, with a 5 cm electrode, always in movement. The duration of the application was established in 20 minutes, maintaining the local temperature between 40ºC to 42 ºC at the epidermis. In this group, the radiofrequency device was switched off.
Study: NCT03169842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pancreatic cyst fluid glucose analysis using a bedside glucometer
Description: Small amount of pancreatic cyst fluid will be analyzed for glucose level using a bedside glucometer from EUS-FNA procedures.
Study: NCT03594812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise protocol - 40 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen´s formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (from 0 to 5 minutes); body (from 5 to 35 minutes); and cooling (from 35 to 40 minutes). The entire protocol was monitored through the Polar® brand heart rate monitor and watch.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Aerobic exercise
Description: Aerobic exercise protocol - 40 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen´s formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (from 0 to 5 minutes); body (from 5 to 35 minutes); and cooling (from 35 to 40 minutes). The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
Study: NCT04361305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine
Description: 30 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 8 weeks Tadalafil 5 mg tablets every day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: 5 mg tablets every day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 5 mg tablets every day for 8 weeks
Study: NCT04545463

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FIBRACEP
Description: A total intake of 7 g/day of FIBRACEP (provided in 6 cookies of 15 g/each) during two months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: INSOLUBLE
Description: A total intake of 7 g/day of wheat bran (provided in 6 cookies of 15 g/each) during two months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SOLUBLE
Description: A total intake of 7 g/day of psyllium plantago (provided in 6 cookies of 15g/each) during two months
Study: NCT05194527

Intervention type: OTHER
Intervention: Biomarker validation and VOC profile identification
Description: Validation of a panel of plasma markers for the early diagnosis of acute intestinal ischemia with a panel consists of I-FABP, VIL-1, and SM22. Identification of an acute intestinal ischemia specific VOCs profile and evaluate exhaled breath analysis as a diagnostic tool for intestinal ischemia.
Study: NCT06318000

Intervention type: OTHER
Intervention: Balance test, bilateral coordination test, fundamental motor skills test
Description: Functional assessment

Intervention type: OTHER
Intervention: Balance test, bilateral coordination test, fundamental motor skills test
Description: Functional assessment
Study: NCT02612194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib was administered orally at 250mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib was administered orally at 250mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib was administered orally at 250mg twice daily
Study: NCT02662374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: .02% Chlorohexidine Gluconate
Description: 5ml of the drug in mouthwash form to be swished four times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: .02% Chlorohexidine Gluconate
Description: 5ml of the drug in mouthwash form to be swished four times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: .02% Chlorohexidine Gluconate
Description: 5ml of the drug in mouthwash form to be swished four times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% Sodium Bicarbonate
Description: 5ml of the drug in the form of a prepared solution to be swished four times a day
Study: NCT02662374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Sodium Bicarbonate
Description: 5ml of the drug in the form of a prepared solution to be swished four times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Sodium Bicarbonate
Description: 5ml of the drug in the form of a prepared solution to be swished four times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nystatin 10000U/ml
Description: 5ml of the drug in mouthwash form to be swished and swallowed four times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nystatin 10000U/ml
Description: 5ml of the drug in mouthwash form to be swished and swallowed four times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nystatin 10000U/ml
Description: 5ml of the drug in mouthwash form to be swished and swallowed four times a day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extra Soft Toothbrush
Description: To be moistened with 0.9% normal Saline and used twice daily to remove dental plaque

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supersaturated Calcium Phosphate
Description: 5ml of the solution to be swished four times a day
Study: NCT04456114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acid etched brackets
Description: The brackets will be bonded to the teeth with composite on the same patient in a split mouth design and observed for bracket debonding for 18 months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sandblasted brackets
Description: The brackets will be bonded to the teeth with composite on the same patient in a split mouth design and observed for bracket debonding for 18 months